U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07023588) titled 'Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease' on June 08.
Brief Summary: A multicenter, open-label, prospective, randomized controlled study to optimize the treatment of patients with acute myeloid leukemia based on early peripheral blood minimal residual disease
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Acute Myeloid Leukemia (AML)
Intervention:
DRUG: Venetoclax
Patients identified with a suboptimal response to chemotherapy based on minimal residual disease (MRD) levels in peripheral blood on Day 6 will initiate ven...